Targeted Oncology30 分钟
MRD Monitoring Post-Transplant Predicts Survival in TP53-Mutant MDS/AML
David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...